Professional Documents
Culture Documents
These include:
References
Rapid responses
Email alerting
service
Receive free email alerts when new articles cite this article - sign up in the box at
the top right corner of the article
Notes
Review
ABSTRACT
Overuse tendinopathy is problematic to manage clinically.
People of different ages with tendons under diverse loads
present with varying degrees of pain, irritability, and
capacity to function. Recovery is similarly variable; some
tendons recover with simple interventions, some remain
resistant to all treatments.
The pathology of tendinopathy has been described as
degenerative or failed healing. Neither of these descriptions fully explains the heterogeneity of presentation. This
review proposes, and provides evidence for, a continuum
of pathology. This model of pathology allows rational
placement of treatments along the continuum.
A new model of tendinopathy and thoughtful treatment
implementation may improve outcomes for those with
tendinopathy. This model is presented for evaluation by
clinicians and researchers.
Review
Despite these varied descriptions of tendon pathology, the
possibility that these may be linked in a continuum has received
limited consideration.12 If a model of pathology can be
developed that is continually evaluated and modified in the
light of research findings, a better understanding of tendon
pathology, treatment and prevention is possible.
Imaging
The tendon is swollen in a fusiform manner; the diameter is
increased on both magnetic resonance imaging (MRI) and
ultrasound (US) scans. Ultrasound shows reflection from intact
collagen fascicles, with diffuse hypoechogenicity occurring
between intact collagen structures. Magnetic resonance imaging
will show minimal or no increased signal at this stage. The
change in imaging appearance is mainly derived from the
increase in bound water within the proteoglycans (fig 2).
Clinical
Reactive tendinopathy is seen clinically in an acutely overloaded
tendon and is more common in a younger person. For example,
a young jumping athlete who dramatically increases the
number of jumping/landing repetitions a week may develop
patellar tendon swelling and pain.
Tendons chronically exposed to low levels of load (e.g. in the
detrained athlete returning from illness or injury, or a sedentary
person) may also be vulnerable to this stage of tendinopathy
when exposed to moderate increase in load. In addition it may
occur as a result of direct trauma to tendon, to which the
Achilles, patellar and elbow tendons are particularly exposed.
2. Tendon dysrepair
Review
Figure 2 (A) Ultrasound image of a
thickened patellar tendon with intact
collagen fascicles. The arrow indicates
the width of the tendon. (B)
Histopathological appearance of reactive
tendinopathy/early tendon dysrepair. Note
the increased cell numbers and
intermittent cell rounding with some
evidence of increased ground substance
(light blue shading) (histology picture by
courtesy of F Bonar).
The changes are somewhat more focal and matrix changes more
varied than in the reactive stage. There may be an increase in
vascularity and associated neuronal ingrowth.18
Clinical
Imaging
The imaging changes reflect increased matrix disorganisation,
and these tendons are swollen, with increasing evidence of
collagen disorganisation. On US there is some discontinuity of
collagen fascicle and small focal areas of hypoechogenicity. The
increase in vascularity may be evident on colour or power
Doppler, and techniques to enhance vascularity (heat, exercise,
hanging the limb) (personal communication, Cormick, 2008)
may show a greater number of vessels. On MRI the tendon is
swollen and there is increased signal within the tendon.
Clinical
This pathology has been reported in chronically overloaded
tendons in the young,19 but may appear across a spectrum of
ages and loading environments. This stage may be hard to
distinguish clinically; these tendons are thick with more
localised changes in one area of the tendon. Tendon dysrepair
is best detected when imaging detects some focal structural
changes with or without increased vascularity.
The frequency, volume or length of time over which load has
been applied (ie, months or years of overload) may be important
variables. An older person with stiffer tendons that have less
adaptive ability may develop this stage of tendinopathy with
relatively lower loads. Some reversibility of the pathology is still
possible with load management and exercise to stimulate
matrix structure.20
3. Degenerative tendinopathy
This stage is clearly described in the literature, with progression
of both matrix and cell changes.8 Areas of cell death due to
apoptosis, trauma or tenocyte exhaustion are apparent.21 As a
result, areas of acellularity have been described, and large areas
of the matrix are disordered and filled with vessels, matrix
breakdown products and little collagen. There is little capacity
for reversibility of pathological changes at this stage. There is
considerable heterogeneity of the matrix in these tendons, with
islands of degenerative pathology interspersed between other
stages of pathology and normal tendon.
Imaging
The compromised matrix and the vascular changes can be
extensive. These appear on ultrasound scans as hypoechoic
regions with few reflections from collagen fascicles. Numerous
and larger vessels are usually visible on Doppler US. Magnetic
resonance imaging demonstrates increased tendon size and
Br J Sports Med 2009;43:409416. doi:10.1136/bjsm.2008.051193
Histopathological studies
Evaluation of human asymptomatic tendons demonstrated that
cell change was always present when matrix change became
apparent.25 Additionally, matrix change was primarily in ground
substance, followed by collagen, and then (theoretically but not
demonstrated) in vascularity. This provides evidence for the
progression from normal to reactive response and tendon
dysrepair; however, this study did not examine tendons that
would be classified as degenerative. Although not considered a
good model for human overuse tendinopathy, animal studies
support these findings. Scott et al16 reported similar progression
in pathology in overloaded rat supraspinatus tendons.
411
Review
Table 1 Stages of osteoarthritis
Feature
Reversible injury
Osteoarthritis
Ageing
Cartilage mass
Hypertrophy
No Change
Cartilage
topographic
distribution
Cartilage water
Cartilage collagen
Focal
Hypertrophy,
erosion
Focal.
Heterogeneous
Oedema
Reversible
deformation
Oedema
Degradation
Reversible
depletion
Resorption
Irreversible
depletion
Accumulative,
collagen,
proteoglycan
Increased activity
and proliferation
Mid focal superficial
inflammation
Dehydration
Increased advanced
glycation end
products
Reduced synthesis
Cartilage
proteoglycan
Cartilage matrix
degeneration
products
Cell activity
Synovium
Bone
Reversibly
increased
Mid focal
superficial
inflammation
No Change
Subchondral
remodelling
Accumulative:
oxidation. Glycation,
amyloid
Reduced
Atrophy
Osteopenia
Reproduced with permission and copyright of the British Editorial Society of Bone
and Joint Surgery. Pollard et al, 2008. The assessment of early osteoarthritis. J Bone
Joint Surg Br;90-B:41121.
Imaging studies
Acute tendon response
An acute bout of exercise increased the MRI volume and signal
in abnormal Achilles tendon.26 This suggests several critical
things: tendon response is rapid, and tendon response is to
increase volume (circumference) and water (either bound as
part of ground substance or in vessels). This is the earliest form
of the reactive response to load proposed in this model.
Reactive to dysrepair
In a group of young athletes at risk of tendon overload and
pathology there was a subgroup with microhypoechoic areas on
US.19 This may represent a transition from reactive to tendon
dysrepair, where small islands of the tendon develop collagen
disorganisation. There is little evidence of reversal of this
transition in the longitudinal studies to date.
Clinical studies
The cumulative effect of load on a tendon has been clearly
demonstrated when the tendon health of athletes who placed
high loads on their Achilles tendons in early adulthood was later
evaluated. Previous elite athletes had a higher cumulative
incidence of tendinopathy and rupture than age-matched
controls.33 As rupture represents end-stage degenerative tendinopathy,23 the higher rupture rates support high chronic load as
an important factor in tendon pathology. This also supports the
non-reversible nature of degenerative pathology, as these older
ex-athletes had not spontaneously recovered tendon health.
The inability of a tendon to recover once it reaches the
degenerative stage is supported by studies that have examined
tendons many years after injury or rupture. Although the
tendons may improve their function, they do not appear to
return to normal size or morphology. Several studies have
shown that large hypoechoic areas do not change,3436 and
similarly tendons used for anterior cruciate ligament graft
replacements remain abnormal for years.37
Review
Figure 3 (A) Ultrasound of a normal
right and tendon dysrepair/degenerative
left patellar tendon. Note the vessel
evident on power Doppler in the left
tendon, the hypoechoic area and the
tendon swelling. (B) Histopathological
appearance of late tendon dysrepair/
degeneration. Note the markedly
increased cell numbers, the loss of
collagen evidenced by the loss of
longitudinal rows of cells, and the
increase in vessels (histology picture by
courtesy of F Bonar).
The source of pain has been associated with neurovascular
ingrowth,38 seen in this model at the late tendon dysrepair/
degenerative phase. However, the fact that tendons can be painful
or pain-free anywhere in this model suggests another or
supplementary cause of pain that has so far proved elusive. The
presence of biochemical substances stimulated by overload
(compression or tension) and/or acting on sensitised nerves in
matrix seems to be one possibility. Cell production of substances
such as catecholamines, acetylcholine and glutamate acting on
their receptors, which allow autocrine/paracrine signalling, has
been described,39 which may explain pain in the cellularly active
stages in this model: reactive and tendon dysrepair.
Pain is the single clinical feature that the clinician seeks to
change, and pain response to treatment is a key indicator of
treatment success. If pain levels and response to load are
considered with the stage of pathology, treatment progression
and outcomes may improve.
Tendinopathic pain is induced by load and has two key
features: (1) dose-dependent pain in relation to singular or
cumulative load, and (2) pain that is well localised to the tendon
or enthesis. Increasing load on the tendon will usually increase
pain. During assessment, the tendon should be provocatively
loaded to functional levels to fully evaluate the level of pain.
Pain should be assessed in the context of the stage and level of
pathology; an extensively degenerated tendon with mild pain
can have insufficient integrity to tolerate high loads and has a
risk of rupture. Conversely, a proliferative tendinopathy is more
reactive and therefore assessment needs to be more conservative
when loading during assessment.
TREATMENT OF TENDINOPATHY
Clinical treatments directed at effecting change in tendon
structure or pathology are considered optimal interventions, but,
as pain is often the clinical presentation, a case can be made for
concentrating on reduction of pain as a valid outcome. It is evident
that pain can occur anywhere in the pathological continuum;
interventions that reduce pain and are also appropriate for the
stage of pathology should, therefore, be our ideal. Conversely,
inappropriate treatments for the stage of pathology (such as
loading up of a tendon in the proliferative phase of tendinopathy) may increase pain, leading to a poor clinical outcome.40
Common interventions and their proposed place in this model are
summarised in table 2. In an effort to maintain clarity of approach,
polymodal interventions, often undertaken in the clinical management of tendinopathy, have not been considered.
Pharmacotherapies
Non-steroidal anti-inflammatory medications (NSAIDs) have
been reported to retard soft tissue healing in a range of tissues.
Although pain may be reduced, they have a negative effect on
tendon repair.42 In reactive tendinopathy, this may be a
preferred effect, as tenocyte upregulation and excess ground
substance expression are apparent in this phase of tendinopathy.25 Ibuprofen (as well as indomethacin and naproxen
sodium) has been shown to inhibit expression of key ground
substance proteins responsible for tendon swelling (aggrecan) in
in-vitro tendon preparations.43 Ibuprofen and celecoxib are also
reported to have a specific effect in downregulating the cellular
response.44 45 Ibuprofen may be favoured as it has not been
shown to have a detrimental effect on ultimate tendon repair.42
Corticosteroids, primarily used to decrease pain, also decrease
cell proliferation and protein production and therefore could be
used in the reactive painful tendon. Repeated peritendinous
corticosteroid has been shown to reduce tendon diameter at 7
and 21 days after injection in tendons.46 Although peritendinous
injection is clinically accepted, it is not known whether
peritendon injection induces cell and matrix change within
the tendon.
Review
Table 2 Clinical and pharmacological treatments placed in the model
Stage
Pharmacological management
Physical management
Reactive
tendinopathy/early
tendon dysrepair
Load management.
Reduction in frequency
intensity of tendon load
Late tendon
dysrepair/
degeneration
Pharmacotherapies
Treatments that stimulate a healing response in the tendon are
appropriate for degenerative tendinopathy. The injection of
various substances around or into the tendon or the process of
injection itself has been proposed to achieve this.
Prolotherapy using glucose and blood injections stimulates a
tissue response. Blood injection stimulates cell proliferation and
production of vascular endothelial growth factor,60 and it has
been demonstrated to induce matrix changes. Clinically, blood
injections have led to reduced vascularity and decreased tendon
diameter on ultrasound.61
Injection itself, regardless of the substances injected, has been
shown to have a beneficial effect on tendon structure. Multiple
tendon biopsies improved structural outcome in degenerative
tendons at 1 year compared with an untreated group,62 and
injections of active (polidocinol) and placebo (anaesthetic and
adrenaline) substances produced similar outcome.63
Aprotinin, a collagenase inhibitor, may preserve collagen in a
remodelling matrix. A recent randomised placebo-controlled
trial did not show benefits of aprotinin over placebo,64 although
earlier studies have shown an effect on pain.65
Sclerosing therapy has repeatedly been shown to be effective
in treating pain and improving structure in tendinopathy.66
When compared with placebo, both pain and structural
outcomes were significantly better with the sclerosing treatment in both Achilles and patellar tendon.67 Interestingly, the
effect on vessels appears to be delayed, with vascularity
increasing in the short term after treatment, suggesting that
the positive effect on pain may be through chemical neurolysis
rather than vascular change.68
414
DISCUSSION
We present a simple and succinct model of tendon pathology,
which is consistent with the clinical presentations of tendinopathy. The aim of this model is to logically order treatment
options for clinicians. Although we have used the term loadinduced tendinopathy, we have deliberately not detailed what
type of load is responsible. Debate on the relative contribution
of tensile, compressive and combined loads is for other fora.
Although these are presented as discrete stages of pathology,
it is highly probable that some tendons may have discrete
regions that are in different stages at the one time. Examination
of tissue, particularly in the latter stages of pathology, often
reveals heterogeneous pathology in a single tendon.81 It is
possible that a tendon with degenerative change that is acutely
overloaded may develop reactive change in previously normal
parts of the tendon. Evaluating these more complex presentations has deliberately not been discussed in this paper to
maintain simplicity. Improving capacity to clinically evaluate
and treat these more difficult tendons is primarily dependent on
accepting the basic model presented.
Br J Sports Med 2009;43:409416. doi:10.1136/bjsm.2008.051193
Review
Research into tendinopathy may also be improved by
considering this model. It is possible that the variable response
to tendon treatment in research studies may be explained to
some extent through the existence of subpopulations of
different pathologies in the investigated cohort. In fact, the
most consistent outcomes in research appear to occur when the
participants are clearly in one group, such as in Alfredsons
eccentric exercise research on older, presurgical patients.
Very little research has been conducted in early-stage
tendinopathy, possibly because of the inherent capacity of
these tendons to spontaneously recover, the variability of pain
presentation and the difficulties in assembling a sizeable cohort.
The individual factors considered earlier (genes, age, circulating and local cytokine production, sex, biomechanics and body
composition) may alter the progression forward or back in the
continuum82 and most are also likely to have an important role
in the response to treatment in tendinopathy. For example,
some athletes appear completely resistant to tendinopathy
despite high loads, and have never been shown to progress into
proliferative tendinopathy. Conversely, other athletes sustain
tendon ruptures relatively early in their careers, presumably
after some degenerative change in the tendon. Identifying
athletes at risk of tendon pathology, as well as using this model
in treatment, may improve outcomes. Early load management
in at-risk athletes may keep them in the early stages of tendon
pathology and limit progression.
Time to recovery should be inherent in a clinical model such
as this; however, the capacity for tendons to transition up and
down between stages makes time estimates for recovery
difficult. Overall, tendons respond very slowly, both in
improving load capacity and in resolving pain.
CONCLUSIONS
This model explains most clinical presentations and most
findings in the tendon literature. It can even encompass primary
collagen tearing83 and some form of inflammation underpinning
the cell and matrix response. Emerging mechanisms for injury,
complex interactions between the cell and matrix and systemic
and local factors (growth factors, cytokines and treatments) will
need to be built into this model. The integrity of the model will
only be as good as its capacity to withstand additional research.
This model now requires scientific and clinical evaluation.
Funding: Jill Cook was funded by a Club Warehouse Visiting Fellowship to the
Australian Institute of Sport Physical Therapies department. Club Warehouse had no
direct or indirect involvement in the production of this manuscript.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
REFERENCES
1.
2.
3.
4.
5.
6.
7.
34.
35.
36.
37.
38.
39.
Kraushaar B, Nirschl R. Tendinosis of the elbow (tennis elbow). Clinical features and
findings of histological, immunohistochemical, and electron microscopy studies.
J Bone Joint Surg Am 1999;81-A:25978.
Ohno K, Yasuda K, Yamamoto N, et al. Effects of complete stress-shielding on the
mechanical properties and histology of in situ frozen patellar tendon. J Orthop Res
1993;11:592602.
Kubo K, Akima H, Ushiyama J, et al. Effects of 20 days of bed rest on the
viscoelastic properties of tendon structures in lower limb muscles. Br J Sports Med
2004;38:32430.
Yamamoto N, Hayashi K, Kuriyama H, et al. Effects of restressing on the mechanical
properties of stress-shielded patellar tendons in rabbits. J Biomech Eng
1996;118:21620.
Neer CS. Impingement lesions. Clin Orthop Related Res 1983;173:707.
Cook JL, Khan KM, Kiss ZS, et al. Asymptomatic hypoechoic regions on patellar
tendon ultrasound: A 4-year clinical and ultrasound followup of 46 tendons.
Scand J Med Sci Sports 2001;11:3217.
Magnusson SP, Narici MV, Maganaris CN, et al. Human tendon behaviour and
adaptation, in vivo. J Physiol 2008;586:7181.
Garau G, Rittweger J, Malliaras P, et al. Traumatic patellar tendinopathy. Disability
and Rheumatism 2008;30:161620.
Scott A, Cook JL, Hart DA, et al. Tenocyte responses to mechanical loading in vivo:
A role for local IGF-I signaling in early tendinosis. Arthritis and Rheumatism. In press.
Samiric T, Ilic MZ, Handley CJ. Characterisation of proteoglycans and their catabolic
products in tendon and explant cultures of tendon. Matrix Biol 2004;23:12740.
Danielson P, Alfredson HK, Forsgren S. Distribution of general (PGP 9.5) and sensory
(substance P/CGRP) innervations in the human patellar tendon. Knee Surg Sports
Traumatol Arthrosc 2006;14:12532.
Cook JL, Khan KM, Kiss ZS, et al. Patellar tendinopathy in junior basketball players: A
controlled clinical and ultrasonographic study of 268 patellar tendons in players aged
1418 years. Scand J Med Sci Sports 2000;10:21620.
Ohberg L, Lorentzon R, Alfredson H. Eccentric training in patients with chronic
Achilles tendinosis: normalised tendon structure and decreased thickness at follow
up. Br J Sports Med 2004;38:811.
Lian O, Scott A, Engebretsen L, et al. Excessive apoptosis in patellar tendinopathy in
athletes. Am J Sports Med 2007;35:60511.
Nehrer S, Breitenseher M, Brodner W, et al. Clinical and sonographic evaluation of
the risk of rupture in the Achilles tendon. Arch Orthop Trauma Surg 1997;116:1418.
Kannus P, Jozsa L. Histopathological changes preceding spontaneous rupture of a
tendon. A controlled study of 891 patients. J Bone Joint Surg Am 1991;73:150725.
Pollard T, Gwilym S, Carr A. The assessment of early osteoarthritis. J Bone Joint
Surg Br 2008;90-B:41121.
Cook JL, Feller JA, Bonar SF, et al. Abnormal tenocyte morphology is more prevalent
than collagen disruption in asymptomatic athletes patellar tendons. J Orthop Res
2004;22:3348.
Shalabi A, Kristoffersen-Wiberg M, Aspelin P, et al. Immediate Achilles tendon
response after strength training evaluated by MRI. Med Sci Sport Exerc
2004;36:18416.
Malliaras P, Cook J. Patellar tendons with normal imaging and pain: Change in
imaging and pain status over a volleyball season. Clin J Sports Med 2006;16:38891.
Cook J, Kiss Z, Khan K, et al. Prospective imaging study of asymptomatic patellar
tendinopathy in elite junior basketball players. J Ultrasound Med 2000;19:4739.
Fredberg U, Bolvig L. Significance of ultrasonographically detected asymptomatic
tendinosis in the patellar and achilles tendons of elite soccer players: a longitudinal
study. Am J Sports Med 2002;30:48891.
Khan KM, Cook JL, Kiss ZS, et al. Patellar tendon ultrasonography and jumpers knee
in female basketball players: A longitudinal study. Clin J Sport Med 1997;7:199206.
Malliaras P, Cook J. Prospective study of change in patellar tendon abnormality on
imaging and pain over a volleyball season. Br J Sports Med 2005;40:2724.
Gisslen K, Alfredson H. Neovascularisation and pain in jumpers knee: a prospective
clinical and sonographic study in elite junior volleyball players. Br J Sports Med
2005;39:4238; discussion 4238.
Kujala UM, Sarna S, Kaprio J. Cumulative incidence of achilles tendon rupture and
tendinopathy in male former elite athletes. Clin J Sport Med 2005;15:1335.
Adriani E, Mariani PP, Maresca G, et al. Healing of the patellar tendon after
harvesting of its mid-third for anterior cruciate ligament reconstruction and evolution
of the unclosed donor site defect. Knee Surg Sports Traumatol Arthrosc 1995;3:138
43.
Karjalainen PT, Aronen HJ, Pihlajamaki HK, et al. Magnetic resonance imaging
during healing of surgically repaired Achilles tendon ruptures. Am J Sports Med
1997;25:16471.
Sanchis-Alfonso V, Subias-Lopez A, Monteagudo-Castro C, et al. Healing of the
patellar tendon donor defect created after central-third patellar tendon autograft
harvest. Knee Surg Sports Traumatol Arthrosc 1999;7:3408.
Kiss ZS, Kellaway DP, Cook JL, et al. Postoperative patellar tendon healing: An
ultrasound study. VIS Tendon Study Group. Australas Radiol 1998;42:2832.
Alfredson H. The chronic painful Achilles and patellar tendon: research on basic
biology and treatment. Scand J Med Sci Sports 2005;15:2529.
Danielson P, Alfredson HK, Forsgren S. Immunohistochemical and histochemical
findings favoring the occurrence of autocrine/paracrine as well as nerve-related
cholinergic effects in chronic painful patellar tendon tendinosis. Microsc Res Tech
2006;69:80819.
415
Review
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
416
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.